[go: up one dir, main page]

WO2009009622A3 - Compositions pharmaceutiques contenant du attm, procédés pour obtenir et conserver le cuivre à un état ciblé et stable et pour prévenir et traiter des maladies du système central nerveux liées au cuivre - Google Patents

Compositions pharmaceutiques contenant du attm, procédés pour obtenir et conserver le cuivre à un état ciblé et stable et pour prévenir et traiter des maladies du système central nerveux liées au cuivre Download PDF

Info

Publication number
WO2009009622A3
WO2009009622A3 PCT/US2008/069567 US2008069567W WO2009009622A3 WO 2009009622 A3 WO2009009622 A3 WO 2009009622A3 US 2008069567 W US2008069567 W US 2008069567W WO 2009009622 A3 WO2009009622 A3 WO 2009009622A3
Authority
WO
WIPO (PCT)
Prior art keywords
copper
pharmaceutical compositions
attm
targeted
maintain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/069567
Other languages
English (en)
Other versions
WO2009009622A2 (fr
Inventor
Steve H Kanzer
John S Althaus
Charles L Bisgaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theriva Biologics Inc
Original Assignee
Pipex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pipex Pharmaceuticals Inc filed Critical Pipex Pharmaceuticals Inc
Publication of WO2009009622A2 publication Critical patent/WO2009009622A2/fr
Publication of WO2009009622A3 publication Critical patent/WO2009009622A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques comprenant une formulation à libération prolongée d'un agent qui induit une malabsorption du cuivre chez un animal ou l'homme. Les compositions pharmaceutiques comprennent, de préférence, des formulations de tétrathromolybdate d'ammonium (ATTM) ayant des tailles de particules ciblées, de préférence, dans la plage de 150 à 700 microns.
PCT/US2008/069567 2007-07-09 2008-07-09 Compositions pharmaceutiques contenant du attm, procédés pour obtenir et conserver le cuivre à un état ciblé et stable et pour prévenir et traiter des maladies du système central nerveux liées au cuivre Ceased WO2009009622A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94868107P 2007-07-09 2007-07-09
US60/948,681 2007-07-09

Publications (2)

Publication Number Publication Date
WO2009009622A2 WO2009009622A2 (fr) 2009-01-15
WO2009009622A3 true WO2009009622A3 (fr) 2009-02-26

Family

ID=40229469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/069567 Ceased WO2009009622A2 (fr) 2007-07-09 2008-07-09 Compositions pharmaceutiques contenant du attm, procédés pour obtenir et conserver le cuivre à un état ciblé et stable et pour prévenir et traiter des maladies du système central nerveux liées au cuivre

Country Status (1)

Country Link
WO (1) WO2009009622A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013712A2 (fr) * 1998-09-04 2000-03-16 The Regents Of The University Of Michigan Methodes et compositions pour la prevention ou le traitement du cancer
WO2004009072A2 (fr) * 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate et composes associes pour therapies anti-angiogeniques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013712A2 (fr) * 1998-09-04 2000-03-16 The Regents Of The University Of Michigan Methodes et compositions pour la prevention ou le traitement du cancer
WO2004009072A2 (fr) * 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate et composes associes pour therapies anti-angiogeniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK KH ET AL: "Inhibition kinetics of mushroom tyrosinase by copper-chelating ammonium tetrathiomolybdate", BIO CHEMICA ET BIOPHYSICA ACTA. GENERAL SUBJECTS, vol. 1726, no. 1, 2005, pages 115 - 120, XP005130387 *

Also Published As

Publication number Publication date
WO2009009622A2 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2006124047A3 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
WO2010011609A3 (fr) Compositions antimicrobiennes à libération contrôlée et procédés pour le traitement de troubles otiques
WO2008116135A3 (fr) Formulations topiques ayant une biodisponibilité amplifiée
WO2007084818A3 (fr) Compositions pharmaceutiques et méthodes permettant d'obtenir et de maintenir un taux de cuivre cible, stable, et de prévenir et de traiter des maladies du système nerveux central liées au taux de cuivre sérique
WO2006042146A3 (fr) Conjugues mutifonctionnels de nanoparticules et utilisation de ceux-ci
WO2008070670A3 (fr) Formulations de topiramate à libération immédiate améliorées
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
MX358592B (es) Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
MX336861B (es) Formulacion de farmaco resistente al abuso.
WO2006108405A3 (fr) Conjugues de nanoparticules et d'agents actifs
WO2007124465A3 (fr) Formules d'émulsions stables
WO2009007328A3 (fr) Utilisation d'homo- et de copolymères pour la stabilisation de formulations de substances actives
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
WO2008010991A3 (fr) Méthodes et compositions pour le traitement du cancer
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2010074992A3 (fr) Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
WO2008042944A3 (fr) Formulations pour soin oral non irritantes
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2006078424A3 (fr) Compositions polyherbales et technique de traitement d'infections virales
WO2010040843A3 (fr) Dérivés dibenzocycloheptanone et agents pharmaceutiques contenant ces composés
WO2006124681A3 (fr) Systeme d'administration orale de medicaments et procedes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781580

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781580

Country of ref document: EP

Kind code of ref document: A2